Venus Remedies has entered Singapore’s topical pain management market with a marketing authorisation and patent for its herbal nanotechnology-based pain reliever Trois. The company is holding talks with various pharmaceutical firms for tie-ups to market Trois in Singapore.
A product for topical use, Trois provides quick and lasting relief to patients suffering from rheumatic disorders, low back pain, osteoarthritis, rheumatoid arthritis, gout, knee pain, ankylosing spondylitis, fibromyalgia and pain originating from muscles and tendons. Currently, more than 1.5 billion people worldwide suffer from chronic pains of varying degree. The company has filed the product, process and use patent for Trois in 46 countries.
Pawan Chaudhary, Chairman and Managing Director said, “This is a great opportunity for us to capture a sizeable share in this segment of the Singapore pharma market. Trois has a huge potential in Singapore.”
“Trois is the safest known topical product for management of pain and inflammation associated with rheumatic disorders. It is 30 per cent more effective than conventional products, as proven by a series of toxicity and safety studies. It has 150 per cent enhanced retention for longer effect, improved relief and better mobility,” said Dr Manu Chaudhary, Joint Managing Director and Director, Research, Venus Remedies.
EP News Bureau- Mumbai
